Security Snapshot

iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) Institutional Ownership

CUSIP: 46565G104

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

0

Shares (Excl. Options)

0

Price

$10.15

Type / Class
Equity / Common stock, par value $0.001 per share
Symbol
ITOS
Shares outstanding
10,000
Price per share
$10.15
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
0
Total reported value
$0
Share change
-232
Value change
-$2,355
Number of holders
0
Price from insider filings
$10.15
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • ITOS - iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share is tracked under CUSIP 46565G104.
  • 0 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • Reported value moved from $2,355 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 46565G104?
CUSIP 46565G104 identifies ITOS - iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
EcoR1 Capital, LLC 28% +87% $78,563,988 +$36,448,488 10,688,978 +87% EcoR1 Capital, LLC 15 May 2025
BlackRock Portfolio Management LLC 6.1% $17,124,228 2,329,827 BlackRock Portfolio Management LLC 31 Mar 2025
BlackRock, Inc. 5.7% $16,018,737 2,179,420 BlackRock, Inc. 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% -50% $15,690,824 -$14,909,254 2,134,806 -49% RA Capital Management, L.P. 15 May 2025
MPM BioVentures 2014, L.P. 4.7% $13,259,371 1,803,996 ANSBERT GADICKE 13 May 2025
TANG CAPITAL MANAGEMENT LLC 100% +900% $101,100 -$38,586,756 10,000 -100% TANG CAPITAL MANAGEMENT, LLC 29 Aug 2025

As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS). This represents 0% of the company’s total 10,000 outstanding shares.

Institutional Holders of iTeos Therapeutics, Inc. - Common stock, par value $0.001 per share (ITOS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$2,355 $10.15 0
2025 Q3 232 $2,355 -$376,633,348 $10.15 1
2025 Q2 37,814,070 $377,007,329 +$70,828,909 $9.97 134
2025 Q1 36,966,178 $220,687,969 +$13,034,816 $5.97 128
2024 Q4 34,139,428 $262,178,251 -$45,399,619 $7.68 133
2024 Q3 36,577,848 $373,304,873 -$1,622,214 $10.21 145
2024 Q2 36,166,048 $536,745,055 +$26,093,561 $14.84 132
2024 Q1 34,550,470 $471,199,415 -$28,496 $13.64 128
2023 Q4 35,010,863 $383,366,744 -$6,188,505 $10.95 131
2023 Q3 35,485,163 $388,561,924 +$7,227,919 $10.95 141
2023 Q2 34,539,222 $457,305,055 -$20,449,873 $13.24 140
2023 Q1 35,981,503 $488,850,445 -$5,820,065 $13.61 149
2022 Q4 36,200,782 $707,271,898 -$15,821,418 $19.53 144
2022 Q3 36,649,009 $698,150,610 -$16,258,800 $19.05 133
2022 Q2 37,263,580 $767,629,385 +$2,327,841 $20.60 147
2022 Q1 35,950,443 $1,156,750,371 +$80,764,252 $32.18 154
2021 Q4 33,399,788 $1,553,374,842 +$104,747,384 $46.56 115
2021 Q3 31,151,490 $841,258,161 +$47,292,624 $27.00 76
2021 Q2 29,465,906 $755,787,849 -$27,400,681 $25.65 82
2021 Q1 30,086,119 $1,028,315,222 +$89,149,616 $34.18 78
2020 Q4 29,256,208 $986,504,074 +$60,467,414 $33.82 72
2020 Q3 24,955,604 $614,284,488 +$614,284,486 $24.67 54

Sponsored